title: Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9.
authors.affiliation: EAU Guidelines Office, Brussels, Belgium. Electronic address: richard.sylvester@skynet.be.
authors.forename: Richard
authors.initials: R
authors.lastname: Sylvester
authors.affiliation: University of Turin, Molinette Hospital, Turin, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Gontero
authors.affiliation: Department of Urology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
authors.forename: Jorg
authors.initials: J
authors.lastname: Oddens
mesh_terms: D000276:Adjuvants, Immunologic; D000283:Administration, Intravesical; D001500:BCG Vaccine; D001407:Bacillus; D002295:Carcinoma, Transitional Cell; D006801:Humans; D009364:Neoplasm Recurrence, Local; D049451:Nomograms; D001749:Urinary Bladder Neoplasms
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine